학술논문
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Original Article
Original Article
Document Type
Clinical report
Author
Goldman, Jason D.; Lye, David C.B.; Hui, David S.; Marks, Kristen M.; Bruno, Raffaele; Montejano, Rocio; Spinner, Christoph D.; Galli, Massimo; Ahn, Mi-Young; Nahass, Ronald G.; Chen, Yao-Shen; SenGupta, Devi; Hyland, Robert H.; Osinusi, Anu O.; Cao, Huyen; Blair, Christiana; Wei, Xuelian; Gaggar, Anuj; Brainard, Diana M.; Towner, William J.; Munoz, Jose; Mullane, Kathleen M.; Marty, Francisco M.; Tashima, Karen T.; Diaz, George; Subramanian, Aruna
Source
The New England Journal of Medicine. Nov 5, 2020, Vol. 383 Issue 19, p1827, 11 p.
Subject
Language
English
ISSN
0028-4793
Abstract
The efficacies of five-day and ten-day treatment courses of remdesivir in patients with severe COVID-19 are evaluated. There were no significant differences in outcomes among patients with five-day and those with ten-day treatment courses.